A Study of HS-10342 in Chinese Patients With HR+/HER2- Advanced and/or Metastatic Breast Cancer

Exclusion Criteria

• •1. Has received or is undergoing the following treatments:
• •1. Currently receiving or have received any CDK4/6 inhibitors;
• •2. Receiving/received antitumor therapy within 14 days or 5 half-lives, before the initial dose whichever is the longer;
• •3. Radiotherapy with a limited field of radiation for palliation within 14 days of the initial dose of study drug, or received more than 30% of the bone marrow irradiation, or large-scale radiotherapy within 28 days of the initial dose.;
• •4. Major surgery within 4 weeks of the initial dose of study drug;
• •5. Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 2 weeks prior to start of study treatment. Meningeal or brainstem metastases. Spinal cord compression;
• •2. Abnormal liver and kidney functions that are known to affect drug metabolism and excretion:
• •3. History of other primary malignancies.
• •4. Participating in other clinical studies.